Over April 28-30th, 2024, on Paradise Island in The Bahamas, the 2024 HEALinc Future Health Summit will be convening experts from across the fields of longevity, cellular medicine, and regenerative health. The event will bring together the world’s top scientists, investors, healthcare providers, longevity tech companies, and stem cell companies. By attending, you will be positioned to learn about cutting-edge future health medicines and technologies that can support peak performance at any age. [Read more…]
Stem Cell Industry Data | 3 Attributes that Make BioInformant Unique
BioInformant specializes in global strategic reports for the stem cell industry. As a specialty research company, we use technology to track and identify profitable opportunities within the stem cell sector and provide this data to clients pursuing aggressive growth.
3 Attributes that Distinguish BioInformant’s Stem Cell Industry Data
1) We are the only market research company that has served the stem cell sector since it emerged
Founded in 2006 in Washington, DC, by Cade Hildreth, our singular focus on the stem cell industry allows us to produce data that enables you to better understand your markets, competitors, and customers.
While other publishers are often broad-scale publishers that cover a range of industry topics, we specialize in stem cell industry data.  In contrast to other research firms, BioInformant has been collecting data on the stem cell industry for the past 12 years. This means we have numerous 5-year periods for which we made stem cell industry projections and can compare our “projected” results to what “actually” occurred within the industry. [Read more…]
RoosterBio Commercializes Industry’s First cGMP Human MSC Banks For Widespread Manufacturing
RoosterBio Launches Only Commercially-Available Working Cell Banks (WCBs) for Large-Scale hMSC Production
Frederick, MD, USA. January 24, 2018 –Â RoosterBio Inc., a leading manufacturer of adult, allogeneic human mesenchymal stem/stromal cells (hMSCs) and paired bioprocess media systems, continues to deliver on its mission to de-bottleneck and accelerate the Regenerative Medicine Industry by launching the only commercially-available working cell banks (WCBs) for large scale hMSC production. [Read more…]
Two-Thirds of All Mesenchymal Stem Cell (MSC) Publications Were Released in the Past 5 Years
In an incredible finding, a search of the PubMed database for scientific publications containing the term “mesenchymal stem cell” or “mesenchymal stem cells” now returns nearly 30,000 results – 28,597 to be exact. (PubMed search of terms “mesenchymal stem cell” and “mesenchymal stem cells” executed July 15, 2016.)
Additionally, mesenchymal stem cell (MSC) scientific publications have increased in number EVERY year since 1992. That is 26 years in a row.
If those numbers haven’t shocked you, then this will” 17,804 of those MSC articles were released in the last 5 years (62%). Meaning, two-thirds of all MSC publications were published in the past 5 years, even though MSCs were discovered by Friedenstein and colleagues in 1976. [Read more…]
6 Reasons Your Survival Depends on Stem Cell Market Intelligence
The first and only market research firm to specialize in the stem cell industry, BioInformant has more than a decade of historical information on all segments of the stem cell market.
The following are six more reasons that your survival depends on stem cell market intelligence. [Read more…]